Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Advaxis Inc (ADXS)

Advaxis Inc (ADXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,720
  • Shares Outstanding, K 60,246
  • Annual Sales, $ 20,880 K
  • Annual Income, $ -16,610 K
  • 60-Month Beta 3.60
  • Price/Sales 2.09
  • Price/Cash Flow N/A
  • Price/Book 1.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.30
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/08/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5658 +25.33%
on 04/24/20
0.8300 -14.57%
on 05/12/20
+0.1201 (+20.39%)
since 04/22/20
3-Month
0.4200 +68.83%
on 03/16/20
0.9600 -26.14%
on 02/24/20
-0.2664 (-27.31%)
since 02/21/20
52-Week
0.2051 +245.73%
on 09/25/19
3.0200 -76.52%
on 05/24/19
-2.2109 (-75.72%)
since 05/22/19

Most Recent Stories

More News
Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA(R) after 16 weeks, including a partial response and stable disease in patients who had most recently progressed...

ADXS : 0.7091 (-2.00%)
Advaxis: Fiscal 1Q Earnings Snapshot

PRINCETON, N.J. (AP) _ Advaxis Inc. (ADXS) on Friday reported a fiscal first-quarter loss of $7.9 million, after reporting a profit in the same period a year earlier.

ADXS : 0.7091 (-2.00%)
Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial...

ADXS : 0.7091 (-2.00%)
Advaxis to Present at the 2020 LD Micro Virtual Conference

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief...

ADXS : 0.7091 (-2.00%)
Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

First two patients treated in the combination arm who previously progressed on KEYTRUDA(R) showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA(R)

ADXS : 0.7091 (-2.00%)
Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting

ADXS : 0.7091 (-2.00%)
Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA compared to an estimated 11 months with Standard...

ADXS : 0.7091 (-2.00%)
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced...

ADXS : 0.7091 (-2.00%)
PSNL : 12.62 (+3.10%)
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced...

ADXS : 0.7091 (-2.00%)
PSNL : 12.62 (+3.10%)
Data on Advaxis' Clinical Programs to be Presented at Upcoming Medical Meetings

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the following upcoming presentations at...

ADXS : 0.7091 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ADXS with:

Business Summary

Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence...

See More

Key Turning Points

2nd Resistance Point 0.7597
1st Resistance Point 0.7344
Last Price 0.7091
1st Support Level 0.6894
2nd Support Level 0.6697

See More

52-Week High 3.0200
Fibonacci 61.8% 1.9447
Fibonacci 50% 1.6126
Fibonacci 38.2% 1.2804
Last Price 0.7091
52-Week Low 0.2051

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar